Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study

Background We conducted an investigator-initiated, phase I trial of vincristine sulfate liposomal injection (VSLI) in combination with bendamustine and rituximab (BR) for indolent B-cell (BCL) or mantle cell lymphoma. Methods Participants received 6 cycles of standard BR with VSLI at patient-specific dose determined by the Escalation with Overdose Control (EWOC) model targeting 33% probability of dose-limiting toxicity (DLT). Maximum tolerated dose (MTD) was the primary endpoint; secondary endpoints included rates of adverse events (AEs), overall response rate (ORR), and complete response (CR). Vincristine sulfate liposomal injection is FDA approved for the treatment of patients with recurrent Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Results Among 10 enrolled patients, VSLI was escalated from 1.80 to 2.24 mg/m(2), with one DLT (ileus) at 2.04 mg/m(2). Two patients discontinued VSLI early. The most common AE included lymphopenia (100%), constipation, nausea, infusion reaction (each 60%), neutropenia, and peripheral neuropathy (50%). Grade 3/4 AE included lymphopenia (90%), neutropenia (20%), and ileus (10%), with prolonged grade >= 2 lymphopenia observed in most patients. Calculated MTD for VSLI was 2.25 mg/m(2) (95% Bayesian credible interval: 2.00-2.40). Overall response was 100% with 50% CR. With median follow-up 26 months, 4/10 patients experienced recurrence and 1 died. Conclusion Vincristine sulfate liposomal injection at 2.25 mg/m(2) can be safely combined with BR for indolent B-cell lymphoma, but given observed toxicities and recurrences, we did not pursue an expanded cohort. Clinical Trials Registration Number: ClinicalTrials.gov identifier NCT02257242.

Automated summary

This study investigated the efficacy and safety of vincristine sulfate liposomal injection in combination with bendamustine and rituximab for indolent B-cell lymphoma. The results showed that the combination therapy was safe and effective, but due to observed toxicities and recurrences, the study did not proceed with an expanded cohort.